Cargando…

Persistence to rivaroxaban therapy for stroke prevention in clinical practice in Italy: Rationale and design of the RITMUS-AF prospective observational cohort study

BACKGROUND: Non-valvular atrial fibrillation (NVAF) is a cardiac rhythm disturbance that increases the risk of stroke and is highly prevalent in Europe and Italy, increasingly with advancing age. Oral anticoagulation is a key component of stroke prevention in patients with NVAF, yet withdrawal or in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piero Perna, Gian, Vora, Pareen, Gandini, Elena, Francesca Lusona, Claudia, Tosarello, Davide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244690/ https://www.ncbi.nlm.nih.gov/pubmed/37292062 http://dx.doi.org/10.1016/j.ijcha.2023.101229

Ejemplares similares

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network
por: Ruigómez, Ana, et al.
Publicado: (2020)

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014)

Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies
por: Vora, Pareen, et al.
Publicado: (2016)

Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2019)

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
por: Leef, George C., et al.
Publicado: (2017)

Electrographic flow–guided ablation in redo patients with persistent atrial fibrillation (FLOW-AF): design and rationale
por: Szili-Torok, Tamas, et al.
Publicado: (2023)

Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care
por: González-Pérez, Antonio, et al.
Publicado: (2022)

Long-Term Adherence and Persistence to Low-Dose Aspirin for the Prevention of Cardiovascular Disease: A Population-Based Cohort Study
por: Vora, Pareen, et al.
Publicado: (2022)

Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

High-resolution Mapping in Patients with Persistent AF
por: Andronache, Marius, et al.
Publicado: (2019)

Erratum to: Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study
por: Durães, André R., et al.
Publicado: (2018)

Prevalence, clinical profile, and stroke risk of atrial fibrillation in rural Andhra Pradesh, India (The AP-AF study) – Rationale and design
por: Saggu, Daljeet Kaur, et al.
Publicado: (2021)

Clinical Implications of Atrial Fibrillation Detection Using Wearable Devices in Patients With Cryptogenic Stroke (CANDLE-AF) Trial: Design and Rationale
por: Jung, Sodam, et al.
Publicado: (2022)

Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
por: Piccini, Jonathan P., et al.
Publicado: (2014)

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation
por: Bassand, Jean-Pierre, et al.
Publicado: (2018)

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
por: Kubitza, Dagmar, et al.
Publicado: (2016)

Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results
por: Savonitto, Stefano, et al.
Publicado: (2020)

Rationale and Design of Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS)
por: Ozaki, Yukio, et al.
Publicado: (2022)

A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial
por: Kotecha, Dipak, et al.
Publicado: (2017)

Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
por: Tervonen, Tommi, et al.
Publicado: (2021)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Intravenous Thrombolysis in a Stroke Patient Receiving Rivaroxaban
por: Fluri, Felix, et al.
Publicado: (2013)

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial
por: Khorana, Alok A., et al.
Publicado: (2017)

Rationale and Design of the Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion Trial (CAPITAL-RAPTOR)
por: Di Santo, Pietro, et al.
Publicado: (2023)

An Observational, Prospective Survey Assessing the Control of Atrial Fibrillation in Asia Pacific: Rationale and Design of the RecordAF-AP Registry
por: Amerena, John, et al.
Publicado: (2011)

Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study
por: Berlin, Sarah, et al.
Publicado: (2020)

Opposite evolution on voltage and thickness from paroxysmal to persistent AF
por: Silva Garcia, E, et al.
Publicado: (2023)

Rationale, Design, and Baseline Characteristics of the BioProsthetic Valves with Atrial Fibrillation (BPV-AF) Study
por: Furukawa, Yutaka, et al.
Publicado: (2020)

A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea
por: Shim, Jaemin, et al.
Publicado: (2021)

Herpes Zoster: the rationale for the introduction of vaccination in Italy
por: PAGANINO, C., et al.
Publicado: (2015)

Corrigendum: Clinical implications of atrial fibrillatioN detection using wearabLE devices in patients with cryptogenic stroke (CANDLE-AF) trial: Design and rationale
por: Jung, Sodam, et al.
Publicado: (2023)

Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial
por: Steinberg, Benjamin A., et al.
Publicado: (2015)

Analyzing Corin–BNP–NEP Protein Pathway Revealing Differential Mechanisms in AF-Related Ischemic Stroke and No AF-Related Ischemic Stroke
por: Shen, Xiaozhu, et al.
Publicado: (2022)

Rivaroxaban concentrations in acute stroke patients with different dosage forms
por: Wada, Shinichi, et al.
Publicado: (2019)

Rivaroxaban administration after acute ischemic stroke: The RELAXED study
por: Yasaka, Masahiro, et al.
Publicado: (2019)

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
por: Diener, H.‐C., et al.
Publicado: (2015)

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery
por: Turpie, Alexander GG, et al.
Publicado: (2012)

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5basitn047vd3kpge3mba4p70n